314 related articles for article (PubMed ID: 24879309)
1. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma.
Mitchell B; Mahalingam M
Histol Histopathol; 2014 Dec; 29(12):1539-46. PubMed ID: 24879309
[TBL] [Abstract][Full Text] [Related]
2. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma--biomarkers of potential utility?
Mitchell B; Leone D; Feller K; Menon S; Bondzie P; Yang S; Park HY; Mahalingam M
Hum Pathol; 2014 Oct; 45(10):2094-100. PubMed ID: 25130395
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
[TBL] [Abstract][Full Text] [Related]
4. Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?
Motlak M; Mathews M; Al-Odat OS; Pandey MK
Cytokine; 2024 Jul; 179():156629. PubMed ID: 38704961
[TBL] [Abstract][Full Text] [Related]
5. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
[TBL] [Abstract][Full Text] [Related]
6. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
7. CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma.
Monteagudo C; Ramos D; Pellín-Carcelén A; Gil R; Callaghan RC; Martín JM; Alonso V; Murgui A; Navarro L; Calabuig S; López-Guerrero JA; Jordá E; Pellín A
Clin Exp Metastasis; 2012 Aug; 29(6):625-37. PubMed ID: 22526457
[TBL] [Abstract][Full Text] [Related]
8. Chemokines in the melanoma metastasis biomarkers portrait.
Neagu M; Constantin C; Longo C
J Immunoassay Immunochem; 2015; 36(6):559-66. PubMed ID: 25839711
[TBL] [Abstract][Full Text] [Related]
9. "CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression".
Franco R; Botti G; Mascolo M; Loquercio G; Liguori G; Ilardi G; Losito S; La Mura A; Calemma R; Ierano C; Bryce J; D'Alterio C; Scala S
Front Biosci (Elite Ed); 2010 Jan; 2(1):13-21. PubMed ID: 20036848
[TBL] [Abstract][Full Text] [Related]
10. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
[TBL] [Abstract][Full Text] [Related]
11. The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review).
Liao YX; Zhou CH; Zeng H; Zuo DQ; Wang ZY; Yin F; Hua YQ; Cai ZD
Int J Mol Med; 2013 Dec; 32(6):1239-46. PubMed ID: 24127013
[TBL] [Abstract][Full Text] [Related]
12. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
13. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
[TBL] [Abstract][Full Text] [Related]
14. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.
Bi J; Li P; Li C; He J; Wang Y; Zhang H; Fan X; Jia R; Ge S
Tumour Biol; 2016 Mar; 37(3):4175-82. PubMed ID: 26490988
[TBL] [Abstract][Full Text] [Related]
15. CXCL14 antagonizes the CXCL12-CXCR4 signaling axis.
Hara T; Tanegashima K
Biomol Concepts; 2014 May; 5(2):167-73. PubMed ID: 25372750
[TBL] [Abstract][Full Text] [Related]
16. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
[TBL] [Abstract][Full Text] [Related]
17. The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer.
Lee HJ; Jo DY
Histol Histopathol; 2012 Sep; 27(9):1155-61. PubMed ID: 22806902
[TBL] [Abstract][Full Text] [Related]
18. Chemokine receptor CXCR4: role in gastrointestinal cancer.
Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
[TBL] [Abstract][Full Text] [Related]
19. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/β-catenin pathway in human colon cancer cells.
Song ZY; Gao ZH; Chu JH; Han XZ; Qu XJ
Biomed Pharmacother; 2015 Apr; 71():46-52. PubMed ID: 25960214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
